Curcuma longa and postprandial glycemia: clinical evidence in overweight individuals

For the reader, the main result is that after 12 weeks, the group receiving the extract showed some more favorable average values compared to the placebo, especially in the late phase of the glucose tolerance test. High-sensitivity C-reactive protein, a biomarker of systemic inflammation but not a disease diagnosis, changed by −0.034 mg/dL in the treated group and by +0.006 mg/dL in the placebo group. Glycated hemoglobin, which roughly reflects the average glycemia of the last few months, changed by −0.08% versus 0.00%.

In the glucose tolerance test, at week 12, glycemia at 120 minutes decreased by 36.1 mg/dL in the treated group and by 24.7 mg/dL in the placebo group; the difference at the individual check was significant. The area under the glycemic curve between 60 and 120 minutes, which is an estimate of glucose exposure in the second hour, also decreased more with the extract: −29.3 versus −20.2 mg·h/dL. The overall group-time effect was not significant for all outcomes. Therefore, the data indicate specific favorable signals, not a uniform improvement in every glycemic or insulin measure.

This work is useful because it examines an identifiable formulation, a defined duration, and repeated clinical measurements. It does not treat turmeric as a generic ingredient: the extract was an 8:1 ratio mixture of an aqueous fraction and a fraction obtained via supercritical carbon dioxide. Consequently, the results are not transferable to the turmeric powder used in cooking, nor to products with curcumin, piperine, or different absorption technologies.

The study links a possible biological pathway to results in humans. Simply put, lower inflammatory signals could be associated with better glucose management after a sugar-rich meal. On a technical level, the authors propose that turmeronols and bisacurone attenuate mediators produced by macrophages and, indirectly, interfere less with insulin signaling. This is biological plausibility, not proof that such a chain of events occurred in the participants.

The results should be interpreted with caution. The efficacy analysis did not include all 110 randomized participants, but rather 81 individuals who adhered to the protocol; this may reduce the robustness compared to an intention-to-treat analysis. Some differences were significant only at individual measurement time points, while several overall group-time analyses were not. The 12-week duration does not allow for the establishment of long-term effects, nor for the evaluation of diabetes prevention or clinical outcomes.

Furthermore, all authors were employees of the company that markets health products; the same company funded the study, designed the protocol, provided the capsules, contributed to the manuscript, and decided on the submission to the journal. Data collection and analysis were performed by a contract research organization. These elements do not invalidate the data, but they increase the need for independent replication. The study does not prove that the extract treats prediabetes, replaces clinical interventions, or is effective for people with diagnosed diabetes.

Initial confirmation concerns the response after meals. Thota and colleagues conducted a randomized crossover study on healthy adults: each participant received, on different occasions, curcumin, curcumin with omega-3, or a placebo before a standardized meal. Curcumin reduced the area under the curve for postprandial insulin by 26% compared to the placebo, though it did not demonstrate a long-term clinical effect. This supports, with a moderate but indirect level of evidence, the hypothesis that certain formulations can modify the acute metabolic response; the product, dose, duration, and population differ from those in Uchio [1].

A second piece of evidence comes from Dolati and colleagues, who randomized 40 sedentary, overweight women into four groups for eight weeks. Curcumin alone reduced fasting glycemia compared to baseline values; the combination with aerobic training improved certain indices of insulin resistance and C-reactive protein. The key takeaway is the convergence between inflammation and metabolism, but the effect of physical activity makes it impossible to attribute all changes to curcumin. The confirmation is therefore indirect and limited by the small sample size [2].

There are relevant conflicting results. In a crossover study of 14 healthy adults, Wickenberg and colleagues administered 6 g of Curcuma longa along with an oral glucose load. They did not observe a significant reduction in postprandial glycemia or the glycemic index; instead, insulin increased at certain time points. This is a direct contrast regarding the immediate glucose response, but it concerns a single dose of the spice in capsules, not the extract studied by Uchio [3].

Kocher and colleagues also did not detect differences in glycemia or inflammatory markers after six weeks of micellar curcuminoids in 42 adults with moderately elevated cholesterol and C-reactive protein, despite an increase in blood curcuminoid levels. Finally, Hellmann and colleagues found no protection against prednisolone-induced insulin resistance in 24 overweight or obese men treated for a short period with 400 mg/day of curcumin. These data show that effect, dose, formulation, and clinical context can change the outcome [4][5].